SEC ownership of CYTOKINETICS INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001061983.
- CIK
- 0001061983
- Symbol
- CYTK on Nasdaq
- Location
- South San Francisco, CA
- Parsed ownership evidence
- 13F and 13D/G
- Lead holder
- T. Rowe Price Investment Management, Inc.
- 13D/G signal
- T. Rowe Price Investment Management, Inc.
- Latest evidence date
- 31 Mar 2026
Ownership snapshot
Top shareholders of CYTOKINETICS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
T. Rowe Price Investment ...
13D/G signal
T. Rowe Price Investment ...
Evidence rows
50
Latest as of
31 Mar 2026
13F
13D/G
Lead comparable stake: 14%
13D/G row: T. Rowe Price Investment Management, Inc.
Showing first 8 of 50 holder rows.
Open remaining rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
Company
|
14%
from 13D/G
|
$1,154,997,000
17,523,840 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
9%
|
$742,940,026
11,135,192 shares
|
-$131,198,475 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.2%
|
$423,276,788
6,422,042 shares
|
$0 | 31 Mar 2026 |
| STATE STREET CORP |
13F
13D/G
Company · STATE STREET CORPORATION
|
4.7%
from 13D/G
|
$378,665,671
5,745,193 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13F
Company
|
13%
|
$1,090,679,433
16,548,011 shares
|
— | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
6.5%
|
$527,905,420
8,009,489 shares
|
— | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
Company
|
4.7%
|
$385,163,672
5,843,782 shares
|
— | 31 Mar 2026 |
| Avoro Capital Advisors LLC |
13F
Company
|
2.7%
|
$219,699,978
3,333,333 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$33,705,091.
Buys
$0
Insiders: 0
Sells
$33,705,091
Insiders: 9
Net
-$33,705,091
Shares: -544,960
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 544,960
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 264,772 | $0 | $17,770,693 | -$17,770,693 |
| 3-6 | 0 | 151,385 | $0 | $9,817,152 | -$9,817,152 |
| 6-9 | 0 | 74,508 | $0 | $4,243,805 | -$4,243,805 |
| 9-12 | 0 | 54,295 | $0 | $1,873,440 | -$1,873,440 |
Reporting owners
Insider holders from Forms 3/4/5
Current reporting-owner rows connected to CYTOKINETICS INC. Open the relationship link for the CIK-to-CIK filing trail.
Rows
24
Lead holder
Robert I. Blum
Net 12M change
-$33,705,090
Latest report
27 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Robert I. Blum | President & CEO, Director | $30,604,984 | -$7,797,322 | -20% | Mixed | 27 May 2026 |
| David Cragg | Chief HR & Admin Officer | $12,476,231 | Mixed | 07 Mar 2022 | ||
| Fady Ibraham Malik | EVP Research & Development | $11,648,842 | -$3,407,270 | -23% | Filing P/S | 19 May 2026 |
| Mark A. Schlossberg | SVP - Legal & General Counsel | $8,419,479 | Mixed | 15 Mar 2022 | ||
| Ching Jaw | SVP Finance & CFO | $7,111,711 | Mixed | 06 Mar 2023 | ||
| Jeffrey Hessekiel | Chief Legal & Admin Officer | $6,760,470 | Mixed | 15 Mar 2026 | ||
| Henderson John T. | Director | $5,152,250 | -$2,078,525 | -29% | Median | 27 May 2026 |
| Sung Lee | EVP, Chief Financial Officer | $4,859,798 | -$2,144,364 | -31% | Filing P/S | 05 May 2026 |
| Andrew Callos | EVP, Chief Commercial Officer | $4,523,373 | -$12,079,808 | -73% | Filing P/S | 05 May 2026 |
| L. Patrick Gage | Director | $2,506,270 | Mixed | 08 Nov 2021 | ||
| Wendell Wierenga | Director | $2,339,014 | -$1,881,925 | -45% | Median | 27 May 2026 |
| Nancy Wysenski | Director | $2,235,469 | Median | 27 May 2026 | ||
| Brett A. Pletcher | EVP, Chief Legal Officer | $1,897,596 | Mixed | 30 Aug 2024 | ||
| Muna Bhanji | Director | $1,737,453 | Median | 27 May 2026 | ||
| Sandford D. Smith | Director | $1,530,777 | Mixed | 02 Jan 2024 | ||
| Robert Arthur Harrington | Director | $1,435,585 | -$248,261 | -15% | Median | 27 May 2026 |
| B. Lynne Parshall | Director | $1,369,873 | -$629,700 | -31% | Median | 27 May 2026 |
| Santo J. Costa | Director | $1,341,266 | Mixed | 15 May 2024 | ||
| Wendall Wierenga | Director | $1,229,433 | Mixed | 15 Jul 2025 | ||
| Robert Wong | VP, Chief Accounting Officer | $960,919 | Mixed | 03 Dec 2024 | ||
| Edward M. Kaye MD | Director | $871,066 | -$3,437,915 | -80% | Median | 27 May 2026 |
| Robert E. Landry | Director | $671,227 | Median | 27 May 2026 | ||
| Robert Califf | Director | $488,764 | Mixed | 03 Jan 2022 | ||
| James M. Daly | Director | $213,482 | Median | 27 May 2026 |
Recent Insider Transactions by Companies or Individuals for CYTOKINETICS INC
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert I. Blum | CYTK | Common Stock | Sale | -1.87% | $579,075 | $77.21 | -7,500 | 392,830 | 27 May 2026 | Direct |
| Muna Bhanji | CYTK | Common Stock | Award | 12.1% | 2,851 | 26,361 | 27 May 2026 | Direct | ||
| Muna Bhanji | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| James M. Daly | CYTK | Common Stock | Award | 734.8% | 2,851 | 3,239 | 27 May 2026 | Direct | ||
| James M. Daly | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Robert Arthur Harrington | CYTK | Common Stock | Award | 15.1% | 2,851 | 21,781 | 27 May 2026 | Direct | ||
| Robert Arthur Harrington | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Henderson John T. | CYTK | Common Stock | Award | 3.79% | 2,851 | 78,088 | 27 May 2026 | Direct | ||
| Henderson John T. | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Edward M. Kaye MD | CYTK | Common Stock | Award | 27.5% | 2,851 | 13,216 | 27 May 2026 | Direct | ||
| Edward M. Kaye MD | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| B. Lynne Parshall | CYTK | Common Stock | Award | 15.9% | 2,851 | 20,784 | 27 May 2026 | Direct | ||
| B. Lynne Parshall | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Robert E. Landry | CYTK | Common Stock | Award | 38.9% | 2,851 | 10,184 | 27 May 2026 | Direct | ||
| Robert E. Landry | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Wendell Wierenga | CYTK | Common Stock | Award | 8.74% | 2,851 | 35,488 | 27 May 2026 | Direct | ||
| Wendell Wierenga | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Nancy Wysenski | CYTK | Common Stock | Award | 9.18% | 2,851 | 33,917 | 27 May 2026 | Direct | ||
| Nancy Wysenski | CYTK | Non-Qualified Stock Option (Right to Buy) | Award | 4,301 | 4,301 | 27 May 2026 | Direct | |||
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $264,915 | $75.69 | -3,500 | 153,902 | 19 May 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 19 May 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -6.81% | -3,500 | 47,886 | 19 May 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.84% | $584,400 | $77.92 | -7,500 | 400,330 | 14 May 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $270,795 | $77.37 | -3,500 | 153,902 | 05 May 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 05 May 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -6.38% | -3,500 | 51,386 | 05 May 2026 | Direct | ||
| Wendell Wierenga | CYTK | Common Stock | Sale | -11% | $302,400 | $75.00 | -4,032 | 32,637 | 05 May 2026 | Direct |
| Wendell Wierenga | CYTK | Common Stock | Options Exercise | 12.4% | 4,032 | 36,669 | 05 May 2026 | Direct | ||
| Wendell Wierenga | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -100% | -4,032 | 0 | 05 May 2026 | Direct | ||
| Sung Lee | CYTK | Common Stock | Sale | -27.4% | $1,837,654 | $76.87 | -23,906 | 63,221 | 05 May 2026 | Direct |
| Henderson John T. | CYTK | Common Stock | Sale | -21% | $1,519,400 | $75.97 | -20,000 | 75,237 | 05 May 2026 | Direct |
| Henderson John T. | CYTK | Common Stock | Options Exercise | 26.6% | 20,000 | 95,237 | 05 May 2026 | Direct | ||
| Henderson John T. | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -100% | -20,000 | 0 | 05 May 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -16.2% | $875,474 | $77.25 | -11,333 | 58,555 | 05 May 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 19.4% | 11,333 | 69,888 | 05 May 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -46.4% | -11,333 | 13,070 | 05 May 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -21.3% | $1,030,705 | $65.00 | -15,857 | 58,555 | 01 May 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 27.1% | 15,857 | 74,412 | 01 May 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -100% | -15,857 | 0 | 01 May 2026 | Direct | ||
| Andrew Callos | CYTK | Common Stock | Sale | -20.4% | $948,900 | $63.26 | -15,000 | 58,555 | 30 Apr 2026 | Direct |
| Andrew Callos | CYTK | Common Stock | Options Exercise | 25.6% | 15,000 | 73,555 | 30 Apr 2026 | Direct | ||
| Andrew Callos | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -21.7% | -15,000 | 54,000 | 30 Apr 2026 | Direct | ||
| Robert I. Blum | CYTK | Common Stock | Sale | -1.81% | $447,150 | $59.62 | -7,500 | 407,830 | 29 Apr 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Sale | -2.22% | $229,915 | $65.69 | -3,500 | 153,902 | 21 Apr 2026 | Direct |
| Fady Ibraham Malik | CYTK | Common Stock | Options Exercise | 2.27% | 3,500 | 157,402 | 21 Apr 2026 | Direct | ||
| Fady Ibraham Malik | CYTK | Non-Qualified Stock Option (Right to Buy) | Options Exercise | -5.99% | -3,500 | 54,886 | 21 Apr 2026 | Direct | ||
| Nancy Wysenski | CYTK | Common Stock | Award | 0.31% | 95 | 31,066 | 15 Apr 2026 | Direct | ||
| Wendell Wierenga | CYTK | Common Stock | Award | 0.29% | 95 | 32,637 | 15 Apr 2026 | Direct | ||
| Edward M. Kaye MD | CYTK | Common Stock | Award | 1.88% | 191 | 10,365 | 15 Apr 2026 | Direct | ||
| Henderson John T. | CYTK | Common Stock | Award | 0.43% | 325 | 75,237 | 15 Apr 2026 | Direct |
An asterisk next to the price means the reported price is likely invalid.